NCT00982657 is a Phase 2 clinical trial of CVX-060 + sunitinib in Solid Tumor, sponsored by Pfizer.

Who is sponsoring NCT00982657?

NCT00982657 is sponsored by Pfizer.

What drugs are being tested in NCT00982657?

Interventions in NCT00982657: CVX-060 + sunitinib, CVX-060 + sunitinib, CVX-060 + sunitinib, CVX-060 + sunitinib, CVX-060 + sunitinib, Sunitinib.

What condition does NCT00982657 study?

NCT00982657 studies Solid Tumor.

Is NCT00982657 still recruiting?

NCT00982657 is currently terminated. Last updated 16 October 2015.

Are results published for NCT00982657?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2015-10-16 · How we verify

NCT00982657

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Terminated Phase 2 Results posted Last updated 16 October 2015

What this trial tests

Phase 2 trial testing CVX-060 + sunitinib in Solid Tumor in 34 participants. Terminated before completion.

Timeline

1 September 2009

Primary endpoint
1 March 2014

1 March 2014

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	1 September 2009
Primary completion	1 March 2014
Estimated completion	1 March 2014
Sites	7 locations across United States

Drugs / interventions tested

CVX-060 + sunitinib — full drug profile →
CVX-060 + sunitinib — full drug profile →
CVX-060 + sunitinib — full drug profile →
CVX-060 + sunitinib — full drug profile →
CVX-060 + sunitinib — full drug profile →
Sunitinib (sunitinib) — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum Tolerated Dose (MTD)
Time frame: Baseline up to Cycle 1( Day 1 to Day 42)
The MTD was defined as the dose level at which less than or equal to (\<=) 1/6 participants experienced Dose Limiting Toxicity (DLT) during the first cycle of treatment with the next higher dose having \>= 2/6 participants with DLT.
Progression-free Survival (PFS)
Time frame: Baseline tumor progression/clinical deterioration or death (up to 28 days post last dose of study medication)
PFS was defined as the time from the first dose date to the first documentation of disease progression or death due to any cause, whichever occurred first.

Sponsor's own description

The safety and tolerability of CVX-060 have been established in the first-in-human clinical trial, CVX-060-101. Thus, this phase Ib/II trial is to assess the safety and pharmacokinetics (PK) profiles of combining CVX-060 with sunitinib in patients with advanced solid tumors, and to subsequently assess the treatment efficacy of the combination treatment, as well as that of sunitinib alone in patients with advanced renal cell carcinoma (mRCC).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Kloepper J, Riedemann L, Amoozgar Z, Seano G, et al · · 2016 · cited 296× · PMID 27044098 · DOI 10.1073/pnas.1525360113
Understanding and targeting resistance to anti-angiogenic therapies.
Clarke JM, Hurwitz HI. · · 2013 · cited 69× · PMID 23997938 · DOI 10.3978/j.issn.2078-6891.2013.036
Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.
Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. · · 2021 · cited 36× · PMID 34125494 · DOI 10.15252/emmm.201708253
Chemically programmed antibodies.
Rader C. · · 2014 · cited 31× · PMID 24630478 · DOI 10.1016/j.tibtech.2014.02.003
Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States.
Ermakov EA, Nevinsky GA, Buneva VN. · · 2020 · cited 23× · PMID 32751323 · DOI 10.3390/ijms21155392

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00982657 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 16 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00982657.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing